ORILISSA 150 MG — DIN 02481332
ELAGOLIX (ELAGOLIX SODIUM) : 150 MG · ABBVIE CORPORATION · TABLET · wholesale supply in Canada
Health Canada status: MARKETED
What is ORILISSA?
ORILISSA 150 MG contains ELAGOLIX (ELAGOLIX SODIUM) : 150 MG. It is listed in the Health Canada Drug Product Database under DIN 02481332, held by ABBVIE CORPORATION, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 30-Oct-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ORILISSA used for?
Treatment of moderate to severe pain associated with endometriosis.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Is there a generic Elagolix in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
Only one market authorization holder has a Canadian DIN containing Elagolix — 2 DINs, of which 2 are currently marketed. There is no second Canadian source today, so a supply interruption on this holder has no domestic substitute at the same molecule.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| ABBVIE CORPORATION | 2 | 2 | ORILISSA | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 150 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | 150 mg: Weekly blisters of 7 tablets (cartons of 28). 200 mg: Weekly blisters of 14 tablets (cartons of 56). |
| Storage | Not explicitly detailed in provided text (section 11 header present but content truncated), though typically 15-30°C for such products. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Elagolix |
|---|---|
| ATC code | H01CC03 |
| AHFS class | 68:18.04 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02481332 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2481332 |
| Brand name | ORILISSA |
| Generic / active ingredient | ELAGOLIX (ELAGOLIX SODIUM) : 150 MG |
| Market authorization holder | ABBVIE CORPORATION |
| Health Canada schedule | Prescription |
| ATC code | H01CC03 |
| ATC anatomical main group | H — Systemic hormonal preparations |
| ATC therapeutic subgroup | H01CC |
| Current status | MARKETED |
| Status date | 30-Oct-2018 |
| Original market date | 2018-10-30 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
150 mg once daily or 200 mg twice daily orally at the same time each day, with or without food. Use lowest effective dose. Limit 200 mg dose to 6 months due to BMD loss.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity; pregnancy or suspected pregnancy; undiagnosed vaginal bleeding; known osteoporosis; severe hepatic impairment (Child-Pugh C); concomitant use of strong OATP1B1 inhibitors.
Warnings and precautions
Dose-dependent decrease in bone mineral density (BMD); hepatic transaminase elevations; suicidal ideation, behavior, and exacerbation of mood disorders; changes in menstrual bleeding patterns.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
2 of 2 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| ORILISSA | 200 MG | TABLET | ABBVIE CORPORATION | MARKETED | 02481340 |
2 · Same class — other molecules in ATC H01CC
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Elagolix | ORILISSA | 2 | 2 | Yes |
| Cetrorelix | CETROTIDE | 2 | 1 | Yes |
| Ganirelix | ORGALUTRAN | 1 | 1 | Yes |
| Relugolix, Estradiol And Norethisterone | MYFEMBREE | 1 | 1 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC H01C
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| H01CB | Lanreotide · Octreotide · Pasireotide · Somatostatin | 49 | 23 |
| H01CA | Gonadorelin · Nafarelin | 4 | 1 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.